2. Signaling Pathways
  3. Antibody-drug Conjugate/ADC Related
  4. ADC Antibody

ADC antibodies act as the navigation system of ADC drugs and are primarily responsible for delivering payloads to target cells.

ADC Antibody Related Products (122):

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-P991503
    Anti-STEAP2 Antibody
    		99.65%
    Anti-STEAP2 Antibody (AZD0516 antibody) is an antibody targeting six-transmembrane epithelial antigen of the prostate 2 (STEAP2). Anti-STEAP2 Antibody can be used for the synthesis of the ADC molecule AZD0516 (HY-173639). Anti-STEAP2 Antibody can be used in the research of prostate cancer.
    Anti-STEAP2 Antibody
  • HY-P990764
    Sigvotatug
    		99.67%
    Sigvotatug (SGN-B6A antibody) is a human IgG1 κ monoclonal antibody against ITGB6. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001). Sigvotatug can be used as an ADC antibody to synthesize ADC Sigvotatug vedotin (HY-164957).
    Sigvotatug
  • HY-P990028
    Raludotatug
    		99.00%
    Raludotatug is a humanized anti-CDH6 IgG1 monoclonal antibody. Raludotatug has antitumor activity and can be used to synthesize the ADC molecule Raludotatug deruxtecan (HY-164734).
    Raludotatug
  • HY-P99711
    Loncastuximab
    		≥99.0%
    Loncastuximab (RB4v1.2) is an anti-CD19 monoclonal antibody. Loncastuximab has antitumor activity and can be used in the research of Non-Hodgkin Lymphoma (NHL) and Diffuse Large B-cell Lymphoma (DLBCL). Loncastuximab is capable of synthesizing the ADC molecule Loncastuximab tesirine (HY-P99349).
    Loncastuximab
  • HY-P99899
    Samrotamab
    		98.26%
    Samrotamab (PR-1498487) is a humanized IgG1-κ chimeric antibody targeting LRRC15. Samrotamab markedly reduces bladder cancer cells viability and inhibits clonogenic growth, migratory and invasive capabilities. Samrotamab significantly increases LRRC15 mRNA level while suppressing SCG5 mRNA expression. Samrotamab can be used for synthesis of ADC ABBV-085.
    Samrotamab
  • HY-P99854
    Disitamab
    		98.70%
    Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (HY-P9985).
    Disitamab
  • HY-P99682
    Ladiratuzumab
    		99.76%
    Ladiratuzumab (hLIV22) is a humanized monoclonal antibody against zinc transporter LIV-1/ZIP6. Ladiratuzumab is conjugated to MMAE (HY-15162) via a cleavable dipeptide linker to synthesize an antibody-drug conjugate (ADC) Ladiratuzumab vedotin (HY-P99683). Ladiratuzumab vedotin selectively targets LIV-1 protein overexpressed on the surface of tumor cells, enters cells through antibody-mediated receptor endocytosis, releases MMAE to inhibit microtubule polymerization, and kills adjacent tumor cells with a bystander effect. Ladiratuzumab can be used in the study of solid tumors such as metastatic triple-negative breast cancer (mTNBC).
    Ladiratuzumab
  • HY-P990047
    Maridebart
    		98.23%
    Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .
    Maridebart
  • HY-P99232
    Indusatumab
    		≥99.0%
    Indusatumab (5F9 Monoclonal antibody) is a monoclonal antibody against human GUCY2C (Guanylate cyclase 2C). Indusatumab fails to bind to granulocytes or erythrocytes. Indusatumab can be used to synthesize ADCs, such as Indusatumab vedotin (HY-P99662). Indusatumab can be used in cancer research.
    Indusatumab
  • HY-P99372
    Lorvotuzumab
    		99.77%
    Lorvotuzumab (Anti-NCAM1/CD56 Reference Antibody (lorvotuzumab)) is a humanized monoclonal antibody that binds CD56 (NCAM1). Lorvotuzumab can be used to synthesize an ADC compound, Lorvotuzumab mertansine.
    Lorvotuzumab
  • HY-P99828
    Cofetuzumab
    		99.31%
    Cofetuzumab (PF-06523435) is a humanized IgG1-κ monoclonal antibody targeting PTK7. The expression system of Cofetuzumab is typically CHO (Chinese hamster ovary) cells. Cofetuzumab downregulates PTK7 expression, modulates its downstream signaling pathways, and inhibits tumor sphere formation of ovarian cancer cells. Cofetuzumab can be used to synthesize the ADC molecule Cofetuzumab pelidotin (HY-P99829). Cofetuzumab is applicable to the research of tumors such as ovarian cancer.
    Cofetuzumab
  • HY-P9915A
    Daratumumab (Anti-CD38)
    Daratumumab (PBS) (Anti-Human CD38) is the first-in-class human-specific anti-CD38 monoclonal antibody (IgG1). Daratumumab (PBS) has anti-multiple myeloma (MM) effect. Daratumumab (PBS) impairs MM cell adhesion, which results in an increased sensitivity of MM to proteasome inhibition.
    Daratumumab (Anti-CD38)
  • HY-P991041
    Turmetabart
    		99.75%
    Turmetabart (Anti-SEZ6 Antibody (SC17)) is a humanized anti-SEZ6 IgG1 monoclonal antibody. Anti-SEZ6 Antibody (SC17) can be used to synthesize antibody-drug conjugates (ADC) product, ABBV-011. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Turmetabart
  • HY-P99352
    Anetumab
    		98.78%
    Anetumab (Anti-MSLN Antibody) is a fully humanized anti mesothelin (MSLN) IgG1 antibody. Anetumab (Anti-MSLN Antibody) can be used to synthesize the ADC molecule Anetumab ravtansine (HY-141606). Anetumab (Anti-MSLN Antibody) can be used for the research of cancer.
    Anetumab
  • HY-P99234
    Pivekimab
    Pivekimab is a human IgG1 monoclonal antibody that targets interleukin-3 (IL-3) and CD123. Pivekimab is used to synthesize pivekimab sunirine, a CD123-directed antibody-active molecule conjugate (ADC). Pivekimab is used in the study of blastic plasmacytoid dendritic cell neoplasm (BPDCN).
    Pivekimab
  • HY-P99101
    Vobramitamab
    		Inhibitor 99.67%
    Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018. MGC018 displays potent antitumor activity in preclinical tumor models of breast, ovarian, and lung cancer, as well as melanoma.
    Vobramitamab
  • HY-P99229
    Upifitamab
    		99%
    Upifitamab is a humanized monoclonal antibody targeting NaPi2b. Upifitamab can be used to synthesize ADC such as Upfitamab rilsodotin. Upfitamab rilsodotin can be used in research for solid tumors including high-grade serious epithelial ovarian, fallopian tube and primary peritoneal cancer (OC). Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).
    Upifitamab
  • HY-P99740
    Mirzotamab
    		99.45%
    Mirzotamab is an IgG1κ monoclonal antibody targeting to CD276/B7-H3 with anti-tumor activity. Mirzotamab conjugates with Clezutoclax (HY-137774), a BCL inhibitor to form Mirzotamab clezutoclax (HY-P99741), involving in research with taxane research in relapsed/refractory solid tumors. Mirzotamab clezutoclax (ABBV-155) is a targeted antibody drug conjugate (ADC).
    Mirzotamab
  • HY-P991506
    Fetrastobart
    		98.63%
    SGN-PDL1V Antibody is a PD-L1 targeting antibody. SGN-PDL1V Antibody can be used for synthesis of ADC SGN-PDL1V (HY-171821).
    Fetrastobart
  • HY-P990947
    Tilatamig
    		99.99%
    Tilatamig (AZD9592 Antibody) is a human antibody of the Ig (G1-κ_G1-λ2) subtype that targets EGFR/MET. Tilatamig conjugates with the Top1 inhibitor AZ14170133 (HY-145399) to form the antibody-drug conjugate (ADC) Tilatamig samrotecan (HY-171124) (AZD9592). Tilatamig accurately targets NSCLC models including EGFR-mutant, EGFR-wildtype, and EGFR tyrosine kinase inhibitor-treated ones, and its activity correlates with high expression of EGFR, c-MET and SLFN11. Tilatamig is available for in vivo anti-tumor studies in patient-derived xenograft models of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC).
    Tilatamig